These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22166329)

  • 1. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
    van Leeuwen PJ; van den Bergh RC; Wolters T; Zhu X; Bul M; Schröder FH; Bangma CH; Roobol MJ
    Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
    Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
    Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Screening for early detection of prostate cancer (first experience in Israel)].
    Neheman A; Shotland Y; Metz Y; Stein A
    Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
    Eggener SE; Roehl KA; Catalona WJ
    J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer.
    Bianco FJ; Mallah KN; Korets R; Hricak H; Scardino PT; Kattan MW
    Urology; 2007 Feb; 69(2):343-6. PubMed ID: 17320675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer risk assessment program: a 10-year update of cancer detection.
    Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
    J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.